Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
88
0

Year Published

2019
2019
2023
2023

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 122 publications
(88 citation statements)
references
References 153 publications
0
88
0
Order By: Relevance
“…The secretory products of pDCs, especially type I IFN, were reported to have both immunogenic and tolerogenic functions in tumor immunity. 157,158 These cytokines contribute to an immunostimulatory TME by promoting the maturation and activation of DCs and proinflammatory macrophages, by increasing the cytotoxicity of NK and T cells, and by facilitating the differentiation of activated B cells into plasma cells; 52,159,160 they also drive an immunosuppressive TME by recruiting Tregs or by inducing the expression of immunomodulatory molecules such as those involved in negative regulatory pathways. 158,160,161 In addition, pDCs can act as professional APCs to regulate antitumor immune responses.…”
Section: Myeloid Cellsmentioning
confidence: 99%
See 1 more Smart Citation
“…The secretory products of pDCs, especially type I IFN, were reported to have both immunogenic and tolerogenic functions in tumor immunity. 157,158 These cytokines contribute to an immunostimulatory TME by promoting the maturation and activation of DCs and proinflammatory macrophages, by increasing the cytotoxicity of NK and T cells, and by facilitating the differentiation of activated B cells into plasma cells; 52,159,160 they also drive an immunosuppressive TME by recruiting Tregs or by inducing the expression of immunomodulatory molecules such as those involved in negative regulatory pathways. 158,160,161 In addition, pDCs can act as professional APCs to regulate antitumor immune responses.…”
Section: Myeloid Cellsmentioning
confidence: 99%
“…158,160,161 In addition, pDCs can act as professional APCs to regulate antitumor immune responses. 157 Thus, the complex roles of pDCs in tumor immunity remain elusive. cDCs consist of two subtypes, described as cDC1s and cDC2s, which demonstrate different phenotypes, functions, and transcriptional factor dependencies.…”
Section: Myeloid Cellsmentioning
confidence: 99%
“…Although they are not generally present in the CNS, they can be recruited in response to pathological stimuli [ 175 ]. Interestingly, in glioma, the TLR9 expression by pDCS is downregulated and both TLR9 and the manipulation of DC activity are proposed to be attractive targets in GBM immunotherapy [ 174 , 175 , 176 , 177 ].…”
Section: Role Of Tspo In Hallmarks Of Gbmmentioning
confidence: 99%
“…Whilst the recent data above points towards a benefit of the infiltration of conventional DC into tumour sites, the correlation between tumour infiltrating pDCs and poor survival prognosis is clear. This has been described in breast, head and neck, ovarian and lung cancers [100][101][102][103] where it is thought that pDCinduced tolerance and impaired IFN-α production contributes to a suppressive, non-immunogenic TME. Indeed mouse studies point to a role of TGF-ÎČ in the tumour environment in preventing an activatory phenotype of pDC and favouring a tolerising, IDO producing phenotype [104].…”
Section: In the Tumour Microenvironmentmentioning
confidence: 93%